tbuckley/cabot-search huggingface dataset:
Valeurs existentielles ou réduction des symptômes?
Authors: Mario Berta
Journal: Psychotherapy and Psychosomatics (1978)

Research Articles| February 16 2010 Valeurs existentielles ou réduction des symptômes? Subject Area: Psychiatry and Psychology Mario Berta Mario Berta Montevideo Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1978) 29 (1-4): 49–57. https://doi.org/10.1159/000287100 Article history Published Online: February 16 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Mario Berta; Valeurs existentielles ou réduction des symptômes?. Psychother Psychosom 31 December 1978; 29 (1-4): 49–57. https://doi.org/10.1159/000287100 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 1978Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?
Authors: S Demehri, P Paschka, B Schultheis, T Lange, T Koizumi, T Sugimoto, S Branford, L-C Lim, T Kegel, G Martinelli, A Hochhaus, B J Druker, M W N Deininger
Journal: Leukemia (2005)
In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat.
Authors: C Cavard, A Zider, M Vernet, M Bennoun, S Saragosti, G Grimber, P Briand
Journal: Journal of Clinical Investigation (1990)

It has been previously shown in vitro that the human immunodeficiency virus type 1 long terminal repeat (LTR) is activated by ultraviolet irradiation. In order to analyze if a similar effect could occur in vivo, transgenic mice carrying the lacZ gene under the control of the viral LTR were irradiated at 280-300 and 254 nm. These mice spontaneously expressed the transgene in the epidermis and the lens of both adults and embryos. Irradiations caused a significant increase in skin beta-galactosidase activity. This phenomenon might be involved in viral activation and could be of interest in regard to the skin pathology observed during an HIV infection.
Tc-99m-MDP Bone Scintigraphy and ???Growing??? Bone Islands: A Report of Two Cases
Authors: DONALD L. ROBACK
Journal: Clinical Nuclear Medicine (1980)

Difficulties in correlation of Tc-99m-MDP bone scintigraphy and radiography of “growing” bone islands were encountered in two cases. The sensitive nature of bone scintigraphy as a metabolic indicator and the slow, inconstant growth rate of bone islands are presumed to cause the difficulties in correlation.
Fatal Pseudomonas Infection in Burned Patients
Authors: Erwin R. Rabin, Charles D. Graber, Edward H. Vogel, Richard A. Finkelstein, Wilfred A. Tumbusch
Journal: New England Journal of Medicine (1961)

PSEUDOMONAS AERUGINOSA (Bacillus pyocyaneus) is normally an organism of low invasiveness and virulence, frequently noted as a local inhabitant of burns, surgical wounds and the genitourinary tract. Under suitable host conditions, however, this gram-negative, motile rod can assume the role of a life-threatening pathogen. Reports of serious pseudomonas infection date back to the 1890's1 although these infections were apparently quite rare before the advent of antibiotics. There is little question that the incidence of serious pseudomonas infection has risen since 1940, and from the spate of reports in the past several years,2 3 4 5 6 7 8 9 10 it is possible that this organism will achieve . . .
Neurotoxicity of Mercury in Dental Amalgam—Reply
Authors: Herbert L. Needleman
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ethics of Phase I Clinical Trials-Reply
Authors: Mortimer B. Lipsett
Journal: JAMA (1983)

<h3>In Reply.—</h3> Both respondents have correctly pointed out that the chief reason for a phase I trial is not therapeutic. I stated that, "First, there is always therapeutic intent" to emphasize this possibility, because some have incorrectly assumed in the past that such does not exist. I agree with Dr Ackerman that my assumption that current safeguards as listed are "generally sufficient" is just that—an assumption. Clinical investigators would welcome any further studies of the process of informed consent, particularly in the difficult situation of phase I trials of cancer chemotherapies.
A Large Brunner's Gland Adenoma removed by Endoscopic Polypectomy
Authors: T. Matsumoto, M. Iida, T. Matsui, T. Yao, M. Fujishima
Journal: Endoscopy (1990)

See also: Endoscopic Removal of Recurrent Duodenal HamartomaEndoscopy 1993; 25(08): 545-546DOI: 10.1055/s-2007-1010396
Anatomy in Surgery
Authors: Darvan A. Moosman
Journal: JAMA (1987)

This 938-page book on surgical anatomy is divided into ten sections covering the head, neck, thorax, abdomen, pelvis, male and female perineum and external genitalia, superior and inferior extremities, and the vertebral column and spinal cord. It has been written by an experienced surgeon for both surgeons and residents in training. The subject is presented in a clear, interesting, and readable manner. The extraneous detail and minutiae found in the usual nonclinical texts of anatomy have been omitted. The illustrations are well chosen, lucid, and pertinent and relate to important and surgically significant structures. Some are in color. The large, clear labeling of the illustrations greatly aids in structure identification. This type of presentation assists in the correlation of anatomy with its surgical application and operative procedures.<i>Anatomy in Surgery</i>will be valuable for those in surgical training and for others who wish to review the anatomy of selected regions.
A Nontoxic Additive to Introduce X-Ray Contrast into Poly(Lactic Acid). Implications for Transient Medical Implants Such as Bioresorbable Coronary Vascular Scaffolds
Authors: Yujing Wang, Nynke M. S. van den Akker, Daniël G. M. Molin, Mick Gagliardi, Cees van der Marel, Martin Lutz, Menno L. W. Knetsch, Leo H. Koole
Journal: Advanced Healthcare Materials (2013)

Abstract Bioresorbable coronary vascular scaffolds are about to revolutionize the landscape of interventional cardiology. These scaffolds, consisting of a poly( L ‐lactic acid) interior and a poly( d,l ‐lactic acid) surface coating, offer a genuine alternative for metallic coronary stents. Perhaps the only remaining drawback is that monitoring during implantation is limited to two X‐ray contrast points. Here, a new approach to make the biodegradable scaffolds entirely radiopaque is explored. A new contrast agent is designed and synthesized. This compound is miscible with poly( d,l ‐lactic acid) matrix, and nontoxic to multiple cell types. Blends of poly( d,l ‐lactic acid) and the contrast agent are found to be hemocompatible, noncytotoxic, and radiopaque. The data show that it is possible to manufacture fully radiopaque bioresorbable coronary vascular scaffolds. Whole‐stent X‐ray visibility helps interventionalists ensure that the scaffold deploys completely. This important advantage may translate into improved safety, accuracy, and clinical performance of cardiac stents.
The Patient with Hypochondriasis
Authors: Arthur J. Barsky
Journal: New England Journal of Medicine (2001)

A 39-year-old woman repeatedly sees her physician for symptoms including paresthesias and "swelling" of the hands and feet. The results of physical examination and laboratory studies have been normal, yet this has failed to reassure her. She is now concerned that she has lupus and urgently requests a rheumatology consultation. How should you manage this problem?
A Family with S and C Hemoglobins and the Hereditary Persistence of F Hemoglobin
Authors: Rose G. Schneider, William C. Levin, Charles Everett
Journal: New England Journal of Medicine (1961)

IT is now generally agreed1 2 3 that there are two varieties of thalassemia, affecting the alpha or beta chain, respectively, of the hemoglobin molecule. The type that affects the beta chain, and is therefore an allele of hemoglobin S or C, is involved in the classic picture of S or C thalassemia disease. Clinically, these conditions manifest a hemolytic anemia milder than that of the corresponding homozygous diseases, sickle-cell anemia or homozygous hemoglobin C disease; they also bear signs of impaired synthesis of hemoglobin A, which is considered the metabolic defect of thalassemia.1 This impaired synthesis is expressed morphologically by a . . .
SERUM THERAPY IN DIPHTHERIA.
Authors: EDWIN ROSENTHAL
Journal: JAMA (1896)

Since the introduction of the diphtheria antitoxin as a specific remedy in diphtheria, I have used it in 127 cases of diphtheria with a record of five deaths. As the character of my cases were in many instances of the most dangerous variety, and in nineteen instances necessitated the operation of intubation, I may not be misjudged if I ascribe to the specific action of antitoxin the results obtained. To briefly summarize my work they are: Tonsillar 67; pharyngeal and tonsillar 14; nasal, pharyngeal and tonsillar 1; pharyngeal 1; laryngeal 12; tonsillarand laryngeal 18; pharyngeal, tonsillar and laryngeal 8; nasal, pharyngeal, tonsillar and laryngeal 4; pharyngeal and laryngeal 2; total 127; number of deaths 5. The ages were: Under 1 year 4 cases; between 1 and 5 years 55 cases; between 5 and 10 years 30 cases; between 10 and 20 years 13 cases; between 20 and 40 years 25
Double-Blind Evaluation of Deanol in Tardive Dyskinesia
Authors: Patricia Penovich
Journal: JAMA (1978)

We administered deanol acetamidobenzoate, 2.0 g/day for four weeks, a double-blind, placebo-controlled crossover trial, to 14 patients with tardive dyskineasia. The patient population included both inpatients and outpatients. The response was evaluated by subjective clinical impression and scoring of filmed sequences. Patients' conditions improved significantly from baseline scores while receiving both deanol and placebo, but there was no distinction between the two treatments.
PROGNOSTIC FACTORS IN RECOVERED AND DETERIORATED SCHIZOPHRENICS
Authors: JOSEPH H. STEPHENS, JOHN C. MANGRUM, CHRISTIAN ASTRUP
Journal: American Journal of Psychiatry (1966)

The case histories of two groups of schizophrenic patients with markedly different outcomes on follow-up were studied by one of us who did not know the outcomes. Of the 54 factors of possible prognostic significance that could be scored as present or absent, 11 were found that differed in the two groups at levels of significance of from p <.05 to p <.001. A scale was used that was made up of those eight of the 11 factors which differed in the two groups at the p <.01 or p <.001 levels. Of the 50 recovered schizophrenics 82 percent had scores of four or more and 80 percent of the deteriorated schizophrenics had scores of less than four. Using an 11-factor scale and a computer method of discriminant functions, an only slightly higher discrimination was possible. The study confirms Vaillant's simple method of prediction of schizophrenic remission and suggests that elaborate subclassifications of schizophrenia may be of less prognostic value than simpler methods which assign patients to a point on a prognostic continuum. The importance of basing prognosis on longitudinal factors as well as on the clinical symptoms present at admission is emphasized. The need for considering prognostic factors in individual patients when evaluating various methods of treatment is apparent.
The Cardiac Renin-Angiotensin System
Authors: David E. Dostal, Kenneth M. Baker
Journal: Circulation Research (1999)

Abstract —Angiotensin II, the effector peptide of the renin-angiotensin system, regulates cellular growth in response to developmental, physiological, and pathological processes. The identification of renin-angiotensin system components and angiotensin II receptors in cardiac tissue suggests the existence of an autocrine/paracrine system that has effects independent of angiotensin II derived from the circulatory system. To be functional, a local renin-angiotensin system should produce sufficient amounts of the autocrine and/or paracrine factor to elicit biological responses, contain the final effector (angiotensin II receptor), and respond to humoral, neural, and/or mechanical stimuli. In this review, we discuss evidence for a functional cardiac renin-angiotensin system.
Randomized Screening Trial for Prostate Cancer in Finland
Authors: Matti Hakama, Jussi Aro, Anssi Auvinen, Harri Juusela, Liisa M&auml;&auml;tt&auml;nen, Ulf-H&aring;kan Stenman, Teuvo L.J. Tammela
Journal: European Urology (2001)
Abstract 4541: Highly sensitive kinase assays combining Carna Biosciences QSS Assist ELISA reagents with the Meso Scale Discovery MULTI-ARRAY platform.
Authors: Carsten Jacobi, Alain Schilb, Yusuke Kawase, Yasuyuki Kirii, Brigitte Boldyreff
Journal: Cancer Research (2013)

Abstract We developed a sensitive kinase asay using a QSS Assist ELISA kinase assay kit from Carna Biosciences, Inc. and the detection method from Meso Scale Discovery. The QSS Assist ELISA kit is optimized for screening of compounds. Comparing to most other kinase assay kits, QSS Assist ELISA kits are available for both peptide and protein substrates and several ELISA kits developed by Carna Biosciences employ a naturally occurring protein substrate, e.g. MAP kinases for MAPK kinases. Detection of kinase activity is achieved with a primary anti-phosphoserine/threonine or tyrosine antibody and a secondary anti-Ig-antibody. Commonly, such secondary antibodies are coupled to horseradish peroxidase (HRP), which allows for signal detection by adding a color reagent, i.e. an HRP substrate which can be detected upon reaction by measuring optical density. Here we applied an MSD SULFO-TAG labeled secondary antibody. These antibodies emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY microplates, and thus detect the primary antibody with ultimate sensitivity without direct labeling it. We have sucessfully miniaturized the highly sensitive assay and this new assay technology has been validated with published kinase inhibitors from AstraZeneca and Tocris Bioscience. Citation Format: Carsten Jacobi, Alain Schilb, Yusuke Kawase, Yasuyuki Kirii, Brigitte Boldyreff. Highly sensitive kinase assays combining Carna Biosciences QSS Assist ELISA reagents with the Meso Scale Discovery MULTI-ARRAY platform. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4541. doi:10.1158/1538-7445.AM2013-4541
Abstract 4888: The novel cytokine IL-17D at the intersection of cellular stress and tumor immunity
Authors: Robert Saddawi-Konefka, Jack Bui
Journal: Cancer Research (2014)

Abstract Our laboratory has recently identified a novel role for the cytokine IL-17D as an important mediator of the antitumor immune response; and, the loss of IL-17D as a key component of tumor progression. Our data show for the first time that overexpression of the cytokine IL-17D is sufficient to induce tumor rejection or growth delay. Tumors expressing IL-17D displayed an increased infiltration of natural killer (NK) cells, which gave way to a commensurate increase of M1-type macrophages. While examining the regulation of IL-17D, we came across the surprising finding that IL-17D can be induced by oxidative stress signals via the transcription factor nrf2. Nrf2, responsible for regulating the expression of the anti-oxidant response element genes, is known as the primary cellular responder to oxidative stress. Although the role of nrf2 in cancer biology has been well studied, the role of nrf2 in the regulation of immune responses (particularly via IL-17D) has yet to be defined. We find that nrf2 is necessary to induce IL-17D expression in a variety of tumor and non-tumor cells, and that this regulation is active in tumor progression. These studies constitute an intriguing and novel connection between oxidative cellular stress and immune activation. Citation Format: Robert Saddawi-Konefka, Jack Bui. The novel cytokine IL-17D at the intersection of cellular stress and tumor immunity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4888. doi:10.1158/1538-7445.AM2014-4888
The Value of Pancreatoscopy in Patients with Mucinous Ductal Ectasia
Authors: D. W. Seo, M. H. Kim, S. K. Lee, B. M. Yoo, S. A. Jung, S. J. Myung, Y. I. Min, G. Gong, Y. H. Auh
Journal: Endoscopy (1997)

We report here on three cases of mucinous ductal ectasia in which the diagnosis was suggested by abdominal computed tomography and finally established by duodenoscopy with pancreatoscopy. Duodenoscopic examination of the ampulla of Vater demonstrated a patulous papillary orifice and extrusion of viscid mucus. Pancreatoscopic examination was carried out in all three patients, and characteristic findings such as papillary or villous mucosal projections coated with whitish gelatinous mucus were noted. In patients with mucinous ductal ectasia in whom the radiographic findings are equivocal, pancreatoscopic examination may provide valuable information for the differential diagnosis of amorphous filling defects in the main pancreatic duct, and may provide information that helps to determine the extent of the pathology and the resection margin.
Pulmonary function during the first year of life in healthy infants born prematurely
Authors: IT Merth, JP de Winter, GJ Borsboom, PH Quanjer
Journal: European Respiratory Journal (1995)

Premature birth is associated with increased respiratory morbidity. We investigated cross-sectionally, in 69 healthy infants who had never had cardiorespiratory problems, whether premature birth is associated with diminished pulmonary function. The study comprised 26 healthy infants born prematurely (PT), median gestational age 32 (26-36) weeks, and 43 healthy controls born full-term (FT), median gestational age 40 (37-42) weeks. Static respiratory system compliance (Crs) was assessed by weighted spirometry, combined with the measurement of the functional residual capacity by closed circuit helium dilution (FRCHe) and with assessment of ventilation distribution from the mixing index (MI). Repeatability of these indices was also assessed. Premature and full-term infants had the same length-corrected FRCHe; their Crs was different, but the difference disappeared when gestational age was taken into account. Mixing index was unrelated to body size and was not different between full-term and premature infants. Crown-heel length and lung volume were not different for any postconceptional age. However, infants born prematurely were smaller and had smaller lung volume at any postnatal age compared to those born at term. Repeatability of the indices was fair. These findings suggest that gestational age &lt; 37 weeks is associated with normal respiratory system mechanics for body size, and normal distribution of ventilation in healthy infants who never had cardiorespiratory problems.
Blood Glucose Variations and Clinical Experience with Glibenclamide in Diabetes Mellitus
Authors: D. J. O'Sullivan, W. F. Cashman
Journal: BMJ (1970)

Thirty patients were treated with glibenclamide for periods up to 16 months. The drug is a potent hypoglycaemic agent, and taken in a single daily dose controls blood glucose levels over a 24-hour period in maturity onset diabetes. A definite dose-effect relationship exists, and the drug may be used in doses of 5 to 20 mg. daily. There were no appreciable side-effects or toxic effects during the period of study.
In vivo imaging of oligonucleotides with positron emission tomography
Authors: Bertrand Tavitian, Salvatore Terrazzino, Bertrand Kühnast, Stéphane Marzabal, Olivier Stettler, Fréderic Dollé, Jean-Robert Deverre, Antoinette Jobert, Françoise Hinnen, Bernard Bendriem, Christian Crouzel, Luigi Di Giamberardino
Journal: Nature Medicine (1998)